Zim Laboratories (NSE:ZIMLAB) PE Ratio: 104.96 (As of Jun. 26, 2026) — 284% Above Median


NSE:ZIMLAB Zim Laboratories Ltd NSE:ZIMLAB
76 GF Score
Price ₹124.90
GF Value ₹102.87
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Zim Laboratories PE Ratio?

Zim Laboratories NSE:ZIMLAB -2.32% 76 PE Ratio is 104.96 as of Jun. 26, 2026, which is 284% above its 10-year median of 27.34. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 76/100 and a GF Value™ of ₹102.87 (Modestly Overvalued). The stock has 8 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-26), Zim Laboratories's share price is ₹124.90. Zim Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1.19. Therefore, Zim Laboratories's PE Ratio for today is 104.96.

Warning Sign:

Zim Laboratories Ltd stock PE Ratio (=100.38) is close to 10-year high of 100.38.

During the past 12 years, Zim Laboratories's highest PE Ratio was 107.48. The lowest was 9.74. And the median was 27.34.

Zim Laboratories's EPS (Diluted) for the three months ended in Mar. 2026 was ₹0.76. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1.19.

As of today (2026-06-26), Zim Laboratories's share price is ₹124.90. Zim Laboratories's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1.19. Therefore, Zim Laboratories's PE Ratio without NRI ratio for today is 104.96.

During the past 12 years, Zim Laboratories's highest PE Ratio without NRI was 107.48. The lowest was 8.85. And the median was 25.21.

Zim Laboratories's EPS without NRI for the three months ended in Mar. 2026 was ₹0.76. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1.19.

During the past 12 months, Zim Laboratories's average EPS without NRI Growth Rate was -66.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was -43.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -13.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was -3.10% per year.

During the past 12 years, Zim Laboratories's highest 3-Year average EPS without NRI Growth Rate was 95.70% per year. The lowest was -44.80% per year. And the median was -2.60% per year.

Zim Laboratories's EPS (Basic) for the three months ended in Mar. 2026 was ₹0.76. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1.19.

Back to Basics: PE Ratio


Zim Laboratories  (NSE:ZIMLAB) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Zim Laboratories PE Ratio Related Terms


Zim Laboratories PE Ratio Historical Data

* Premium members only.

The historical data trend for Zim Laboratories's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zim Laboratories PE Ratio Chart

Zim Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.82 14.45 26.98 32.08 50.31

Zim Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.08 57.66 52.27 49.92 50.31

NSE:ZIMLAB vs ZTS: PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zim Laboratories PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's PE Ratio distribution charts can be found below:

* The bar in red indicates where Zim Laboratories's PE Ratio falls into.


NSE:ZIMLAB
76GF Score
Zim Laboratories Ltd NSE:ZIMLAB
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zim Laboratories PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Zim Laboratories's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=124.90/1.190
=104.96

Zim Laboratories's Share Price of today is ₹124.90.
Zim Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1.19.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 104.96 mean?
Zim Laboratories (NSE:ZIMLAB) has a PE Ratio of 104.96 as of Jun. 26, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Zim Laboratories and its competitors. This is 284% above median its historical median of 27.34. Over the past decade, Zim Laboratories' PE Ratio has ranged from 9.74 to 107.48.
Is Zim Laboratories' PE Ratio too high?
Zim Laboratories' current PE Ratio of 104.96 is 284% above median its 10-year median of 27.34. Over the past 10 years, this metric has ranged from a low of 9.74 to a high of 107.48. Overall, Zim Laboratories has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' PE Ratio compare to ZTS?
Zim Laboratories' PE Ratio of 104.96 can be compared against companies in the Drug Manufacturers industry. Historically, Zim Laboratories' own PE Ratio has ranged from 9.74 to 107.48 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Drug Manufacturers company?
A good PE Ratio depends on the Drug Manufacturers industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Zim Laboratories and its competitors. Zim Laboratories's current PE Ratio is 104.96, which is 284% above median its own 10-year median of 27.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹102.87, compared to a current price of ₹124.90 — trading 21.4% above its estimated fair value. The current PE Ratio is 104.96, which is 284% above median its 10-year median of 27.34. Zim Laboratories' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current PE Ratio is 104.96 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued. The current stock price of ₹124.90 is trading 21.4% above its estimated GF Value™ of ₹102.87. GuruFocus considers Zim Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:ZIMLAB:

  • PE Ratio: 104.96 (284% above median its 10-year median of 27.34)
  • GF Value™: ₹102.87 vs. price of ₹124.90 (21.4% above fair value)
  • GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zim Laboratories Business Description

Other Exchanges 541400:India
Address Nelson Square, Chhindwara Road, Sadoday Gyan, Ground Floor, Opposite NADT, Nagpur, MH, IND, 440 013
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
76GF Score

Get the complete analysis for NSE:ZIMLAB

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹124.90
Price
₹102.87
GF Value